MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Second Quarter 2009 Financial and Operational Results

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is scheduled to announce its financial results for the 2009 second quarter on Thursday, August 6, 2009, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review results for the 2009 second quarter.

To listen live to the call, dial 1-800-813-8504 or 1-660-422-4526. A replay of the call will be available starting at approximately 11 a.m. on August 6 through 5 p.m. on August 13, 2009. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291, and enter the conference ID #19864871.

A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, www.middlebrookpharma.com. A replay of the webcast will be available starting at approximately 11 a.m. on August 7 through 5 p.m. on Sept. 4, 2009.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. The Company has developed a proprietary delivery technology called PULSYS�, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MiddleBrook is currently developing a portfolio of anti-infective PULSYS products. The Company�s near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which it believes will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG � the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024